On March 17, 2025, Avidity Biosciences announced positive topline data from the Phase 1/2 EXPLORE44 trial for delpacibart zotadirsen (del-zota), showing a 40% increase in exon 44 skipping and a 25% increase in dystrophin production among participants, with plans for a Biologics License Application by the end of 2025.